ArticleHealth science reports2025
Diagnostic Significance of Serum Ferritin and Hepcidin as Complementary Biomarkers for Prostate Disease: A Prospective Case-Control Study in a Mission Hospital, Ghana.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Currently, available evidence suggests prostate-specific antigen (PSA) is highly sensitive but poorly specific for prostate cancer detection in symptomatic patients and those with lower urinary tract symptoms. Serum ferritin and hepcidin, which are implicated in the pathogenesis of prostate cancers, may complement the diagnostic value of PSA. This study explored the correlation of serum PSA with ferritin and hepcidin as new and complementary diagnostic biomarkers for prostate disease. Methods: This hospital-based case-control study was conducted at Methodist Hospital, Wenchi, with 90 participants. Venous blood sample was taken for complete blood count, PSA, ferritin, and hepcidin measurements using Mindray automated hematology analyzer and ELISA, respectively. Data were analyzed with SPSS version 27, and Results: Serum PSA levels were significantly higher among the Prostate Cancer patients compared to BPE patients [32.1 (18.2-47.6) vs. 18.3 (12.2-0.6), Conclusion: High levels of serum ferritin and hepcidin significantly correlated directly with increased serum total PSA levels and could play a valuable role to complement the noninvasive total PSA to improve diagnostic accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.